Gilead Sciences Inc. (GILD) –Nasdaq   GILD dropping hard after MRK receive the FDA approval for a less expensive alternative to Gilead’s hepatitis C drug and pricing it with more than 30% discount to the competitor drugs from Gilead and ABBV. We notices a huge Feb 19th call options activity, with over 25K of $89 Call […]